Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Evaluate's commercial intelligence on the pharmaceutical, biotechnology, and medical device industries is consistently referenced by leading business and industry publications such as the Financial Times, Wall Street Journal, and Nature.
Download our latest Media Kit for a forward-looking view of top companies, products, and more to support your editorial content.
Eleventh annual EvaluatePharma World Preview 2018, Outlook to 2024 report launches at BIO 2018.
Annual “EvaluatePharma Orphan Drug 2018 Report” sees Orphan drugs capture a fifth of worldwide prescription sales by 2024 as sales grow to $262bn.
EP Vantage releases its annual analysis of sector performance: Pharma, Biotech and Medtech 2017 in Review.
The problem comes when reality catches up with the froth, as Australia’s Neuren Pharma found out last week, said EP Vantage, the editorial arm of the Evaluate…
Biosimilars the beneficiary of new Medicare step therapy rule (EP Vantage)
Today, pharma companies have a lot to gain by developing drugs for rare diseases. Evaluate Pharma’s Orphan Drug 2018 Report forecasts an 11 percent per annum…